Product Name: (–)–DHMEQ
Cat. No.: HY-14645
CAS No.: 287194-40-5
Molecular Formula: C13H11NO5
Molecular Weight: 261.23
Target: NF–κB
Solubility: DMSO: ≥ 32 mg/mL

Inhibitors, Agonists, Screening Libraries
www.MedChemExpress.com

BIOLOGICAL ACTIVITY:

(–)–DHMEQ, the eutomer of DHMEQ, is a newly developed NF–κB inhibitor, inhibits nuclear factor kB activation with IC50 value of 20 ug/mL, the activity is stronger than (+)–DHMEQ (HY–14645A).

Target: NF–κB [1]
IC 50: 20 ug/mL [2]

In vitro: (–)–DHMEQ significantly reduces eosinophilic airway inflammation and levels of Th2 cytokines in bronchoalveolar lavage fluid in the acute model. It also inhibits parameters of airway remodelling including mucus production, peribronchial fibrosis and the expression of a–smooth muscle actin.[1] (–)–DHMEQ strongly inhibits cyclin D1 and vascular endothelial growth factor (VEGF) promoter activity and decreased the levels of cyclin D1 protein and VEGF mRNA in KB cells;[2] (–)–DHMEQ strongly inhibits cyclin D1 and vascular endothelial growth factor (VEGF) promoter activity and decreased the levels of cyclin D1 protein and VEGF mRNA in KB cells.[2] (–)–DHMEQ suppresses the tumour growth and anti-inflammatory effects.[3] (–)–DHMEQ inhibits TPA–induced activation of NF–κB and differentiation of THP–1 cells into macrophages.[5]

In vivo: When (–)–DHMEQ is injects into mice 2 h before LPS injection, the survival of the LPS–injected mice was prolonged. When (–)–DHMEQ is injected twice (2 h before LPS injection and the day after LPS injection), all the mice are rescued. (–)–DHMEQ can be utilized for the prevention and treatment of endotoxin shock.[3]

References:

Caution: Product has not been fully validated for medical applications. For research use only.